AR001

AR001 is a code name associated with two distinct experimental therapeutic agents. The first is a selective **adenosine A1 receptor agonist** (CAS 681475-23-0) that has demonstrated hypnotic efficacy in animal models, suggesting potential for the treatment of **insomnia**. It functions by increasing the expression and mRNA levels of the adenosine A1 receptor in the hypothalamus. The second is a preclinical-stage drug being developed by **Aeon Respire** for the treatment of **cystic fibrosis** and other respiratory, immune, and digestive system disorders. This version of AR001 is designed to address mucus-related pathologies and inflammation in the lungs.

Other names

N6-cyclohexyl-2'-O-methyladenosine